UK: Patents granted to Doudna-Charpentier

The United Kingdom’s Intellectual Property Office awarded two patents to the Doudna-Charpentier team, with the first UK patent covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). This patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease. A second UK patent focuses on modified Cas9 that incorporates additional DNA-modulating functions such as the regulation of gene expression.



Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issued U.S. Patent No. 10,266,850 (‘the ‘850 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)
U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
Read moreArrow-down